

Canada Diabetes Care Drugs And Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-08-01 | 125 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Canada Diabetes Care Drugs And Devices Market Analysis

The Canada Diabetes Care Drugs And Devices Market size is estimated at USD 6.66 billion in 2025, and is expected to reach USD 8.19 billion by 2030, at a CAGR of 4.22% during the forecast period (2025-2030).

Universal pharmacare, population ageing and rapid device innovation act together to keep demand on a stable upward track. Federal coverage for diabetes medicines, provincial funding for continuous glucose monitoring (CGM) and insulin pumps, and the arrival of once-weekly insulins are broadening patient access while lifting revenue visibility for suppliers. Strategic alliances that join sensors, pumps and decision-support software are reshaping competitive boundaries, and private insurers have started testing premium models tied to glycemic outcomes. Nevertheless, disparate provincial tendering practices, high out-of-pocket insulin costs and privacy concerns in cloud-based monitoring continue to temper the adoption pace.

Canada Diabetes Care Drugs And Devices Market Trends and Insights

Increasing Prevalence of Type 2 Diabetes

Diagnosed cases are set to jump from 4 million in 2024 to 5.2 million by 2030, equal to nearly 13% of Canadian adults. Indigenous communities face a 17.2% prevalence rate, and Black Canadians experience double the mortality risk compared with white Canadians. More than 7,700 diabetes-related lower-limb amputations occur each year, 85% of which are preventable with timely

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

intervention . Provincial disparities widen market opportunities-for example, Saskatchewan already counts 29% of residents living with diabetes or pre-diabetes, while Alberta's 28% prevalence equates to 587,710 diagnosed patients and USD 556 million in direct medical costs. Over the next decade, the economic burden is forecast to exceed USD 15.3 billion, underscoring the value of preventive devices and integrated care models that demonstrate measurable outcome improvements.

Government Reimbursement Expansion for CGM & Pumps

Nova Scotia broadened public funding for insulin pumps and CGM in February 2024, and Saskatchewan now fully covers Dexcom G6 and G7 sensors for eligible residents, eliminating out-of-pocket costs . FreeStyle Libre 2 is publicly reimbursed in most provinces; Ontario's drug program funds 33 sensors a year for insulin-dependent patients, while Quebec reimburses children under 18 and adults on intensive insulin therapy. In British Columbia, a four-year USD 670 million pharmacare deal will deliver universal diabetes coverage from March 2026.

High Out-of-Pocket Cost for Long-Acting Analog Insulins

Canadian spending on antidiabetic drugs doubled to USD 2.7 billion between 2012 and 2021, with list prices remaining above peer-country levels, adding USD 703 million in excess costs. Blood-glucose test strips average USD 0.79 each, yet reimbursement thresholds differ widely by province, and Quebec residents pay nearly USD 500 per month for Ozempic when prescribed for weight management rather than diabetes. Downstream complications inflate system expenses; diabetes-related amputations alone exceed USD 750 million annually.

Other drivers and restraints analyzed in the detailed report include:

Uptake of Once-Weekly and Oral GLP-1s / Digital Therapeutics Linked to Insurance Premiums / Fragmented Provincial Tendering Delays Device Adoption /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Drugs captured 65.67% of the Canada diabetes care drugs and devices market share in 2024, reflecting entrenched use of insulin analogues and GLP-1 receptor agonists. Novo Nordisk's diabetes care division posted DKK 290.4 billion in 2024 sales, a 25% jump that underscores the segment's resilience. Still, the devices category is slated for the fastest advance at a 4.98% CAGR to 2030. Monitoring devices form the largest slice; CGM adoption continues to displace finger-stick meters as public and private plans expand reimbursement coverage. Management devices such as hybrid closed-loop pumps are scaling quickly, helped by Abbott-Medtronic integration that links FreeStyle Libre sensors to automated delivery algorithms, broadening the addressable user base and opening a USD 100 million incremental sales channel for Abbott.

Market participants are refining go-to-market tactics. Abbott emphasizes affordability to penetrate the Type 2 population, whereas Dexcom keeps focus on the intensive insulin cohort where alarm accuracy and real-time data sharing command premium pricing. Tandem Diabetes Care's t:slim X2 pump integrated with Dexcom G7 won notice among Canadian endocrinologists because software upgrades are delivered online, cutting replacement cycles and supporting iterative innovation. Collectively, these trends keep the devices segment central to value creation even though drugs still dominate total revenue.

The Canada diabetes care drugs and devices market size for Type 2 patients accounted for USD 6.0 billion in 2025, equal to 90.12% of total market revenue. Expanded GLP-1 indications for cardiovascular and renal protection reinforce this concentration, yet Type 1 is positioned for a faster 5.03% CAGR, powered by technology-intensive therapy. Health Canada approved Insulet's

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Omnipod 5 automated insulin delivery system in April 2024, giving Type 1 users a tubeless option that integrates with Dexcom sensors and smartphone control. Type 1 households show higher device penetration because sustained exogenous insulin demands favour adoption of closed-loop systems that reduce hypo- and hyper-glycemic excursions.

Within Type 2, weekly insulins and oral GLP-1s are attracting patients who previously relied solely on tablets. Cardiovascular-outcome data for semaglutide and dapagliflozin have made combination therapy more common in primary care. Gestational diabetes care remains a small but technically dynamic subsegment; researchers reviewing 15 mobile apps found only three offered culturally relevant features, highlighting product gaps for diverse Canadian families. Vendors able to overlay French and Indigenous-language support may capture outsized loyalty in Quebec and remote communities respectively.

The Canada Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

Novo Nordisk / Sanofi / Eli Lilly and Company / AstraZeneca / Boehringer Ingelheim / Bristol-Myers Squibb / Roche / Abbott Laboratories / Johnson & Johnson / Arkray / Ascensia / AgaMatrix / Dexcom / Medtronic / Beckton Dickinson / Ypsomed / Terumo / Tandem Diabetes Care / Insulet / LMC Diabetes & Endocrinology / Bayshore Health Care / Express Scripts Canada / One Drop / TELUS Health /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

- 1 Introduction
 - 1.1 Study Assumptions & Market Definition
 - 1.2 Scope of the Study
- 2 Research Methodology
- 3 Executive Summary
- 4 Market Landscape
 - 4.1 Market Overview
 - 4.2 Market Drivers
 - 4.2.1 Increasing prevalence of Type-2 diabetes
 - 4.2.2 Government reimbursement expansion for CGM & pumps
 - 4.2.3 Uptake of once-weekly and oral GLP-1s
 - 4.2.4 Digital-therapeutic integrations with HbA1c-linked insurance premiums
 - 4.2.5 Venture investment surge in Canadian diabetes tech start-ups
 - 4.2.6 AI-driven closed-loop for smart pens and phone ecosystems
 - 4.3 Market Restraints
 - 4.3.1 High out-of-pocket cost for long-acting analog insulins
 - 4.3.2 Fragmented provincial tendering delays device adoption

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.3 Data-privacy concerns slowing cloud-based monitoring
- 4.3.4 Limited French-language support in mobile apps affecting Quebec uptake
- 4.4 Regulatory Landscape
- 4.5 Technological Outlook
- 4.6 Porters Five Forces Analysis
 - 4.6.1 Bargaining Power of Suppliers
 - 4.6.2 Bargaining Power of Consumers
 - 4.6.3 Threat of New Entrants
 - 4.6.4 Threat of Substitutes
 - 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

- 5.1 By Product Type
 - 5.1.1 Devices
 - 5.1.1.1 Monitoring Devices
 - 5.1.1.1.1 Self-Monitoring Blood Glucose Meters
 - 5.1.1.1.2 Continuous Glucose Monitoring Systems
 - 5.1.1.2 Management Devices
 - 5.1.2 Drugs
 - 5.1.2.1 Oral Anti-Diabetic Drugs
 - 5.1.2.2 Insulin Drugs
 - 5.1.2.3 Non-Insulin Injectables
 - 5.1.2.4 Combination Drugs
- 5.2 By Diabetes Type
 - 5.2.1 Type 1 Diabetes
 - 5.2.2 Type 2 Diabetes
- 5.3 By Age Group
 - 5.3.1 Adult
 - 5.3.2 Geriatric
 - 5.3.3 Pediatric
- 5.4 By Distribution Channel
 - 5.4.1 Offline
 - 5.4.2 Online

6 Competitive Landscape

- 6.1 Market Concentration
- 6.2 Market Share Analysis
- 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
 - 6.3.1 Novo Nordisk A/S
 - 6.3.2 Sanofi
 - 6.3.3 Eli Lilly & Co.
 - 6.3.4 AstraZeneca
 - 6.3.5 Boehringer Ingelheim
 - 6.3.6 Bristol Myers Squibb
 - 6.3.7 Roche
 - 6.3.8 Abbott

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.9 Johnson & Johnson
- 6.3.10 Arkray
- 6.3.11 Ascensia Diabetes Care
- 6.3.12 AgaMatrix
- 6.3.13 Dexcom
- 6.3.14 Medtronic
- 6.3.15 Becton Dickinson
- 6.3.16 Ypsomed
- 6.3.17 Terumo
- 6.3.18 Tandem Diabetes Care
- 6.3.19 Insulet
- 6.3.20 LMC Diabetes & Endocrinology
- 6.3.21 Bayshore HealthCare
- 6.3.22 Express Scripts Canada
- 6.3.23 One Drop
- 6.3.24 Telus Health

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-Need Assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Canada Diabetes Care Drugs And Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-08-01 | 125 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-01"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

